Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

Clinical findings, pathology, and outcomes of C3GN after kidney transplantation.

Zand L, Lorenz EC, Cosio FG, Fervenza FC, Nasr SH, Gandhi MJ, Smith RJ, Sethi S.

J Am Soc Nephrol. 2014 May;25(5):1110-7. doi: 10.1681/ASN.2013070715. Epub 2013 Dec 19.

2.

C3 glomerulonephritis: clinicopathological findings, complement abnormalities, glomerular proteomic profile, treatment, and follow-up.

Sethi S, Fervenza FC, Zhang Y, Zand L, Vrana JA, Nasr SH, Theis JD, Dogan A, Smith RJ.

Kidney Int. 2012 Aug;82(4):465-73.

3.

Clinico-pathologic spectrum of C3 glomerulopathy-an Indian experience.

Viswanathan GK, Nada R, Kumar A, Ramachandran R, Rayat CS, Jha V, Sakhuja V, Joshi K.

Diagn Pathol. 2015 Mar 17;10:6. doi: 10.1186/s13000-015-0233-0.

4.

C3 glomerulopathy: clinicopathologic features and predictors of outcome.

Medjeral-Thomas NR, O'Shaughnessy MM, O'Regan JA, Traynor C, Flanagan M, Wong L, Teoh CW, Awan A, Waldron M, Cairns T, O'Kelly P, Dorman AM, Pickering MC, Conlon PJ, Cook HT.

Clin J Am Soc Nephrol. 2014 Jan;9(1):46-53. doi: 10.2215/CJN.04700513. Epub 2013 Oct 31.

5.

Membranoproliferative glomerulonephritis and C3 glomerulonephritis: frequency, clinical features, and outcome in children.

Okuda Y, Ishikura K, Hamada R, Harada R, Sakai T, Hamasaki Y, Hataya H, Fukuzawa R, Ogata K, Honda M.

Nephrology (Carlton). 2015 Apr;20(4):286-92. doi: 10.1111/nep.12382.

PMID:
25524631
6.

Eculizumab and recurrent C3 glomerulonephritis.

Gurkan S, Fyfe B, Weiss L, Xiao X, Zhang Y, Smith RJ.

Pediatr Nephrol. 2013 Oct;28(10):1975-81. doi: 10.1007/s00467-013-2503-y. Epub 2013 May 22.

7.

C3 glomerulonephritis associated with monoclonal gammopathy: a case series.

Zand L, Kattah A, Fervenza FC, Smith RJ, Nasr SH, Zhang Y, Vrana JA, Leung N, Cornell LD, Sethi S.

Am J Kidney Dis. 2013 Sep;62(3):506-14. doi: 10.1053/j.ajkd.2013.02.370. Epub 2013 Apr 26.

8.

Defining the complement biomarker profile of C3 glomerulopathy.

Zhang Y, Nester CM, Martin B, Skjoedt MO, Meyer NC, Shao D, Borsa N, Palarasah Y, Smith RJ.

Clin J Am Soc Nephrol. 2014 Nov 7;9(11):1876-82. doi: 10.2215/CJN.01820214. Epub 2014 Oct 23.

9.

C3 glomerulopathy.

Servais A, Noël LH, Frémeaux-Bacchi V, Lesavre P.

Contrib Nephrol. 2013;181:185-93. doi: 10.1159/000348654. Epub 2013 May 8. Review.

PMID:
23689580
10.

Membranoproliferative glomerulonephritis recurrence after kidney transplantation: using the new classification.

Alasfar S, Carter-Monroe N, Rosenberg AZ, Montgomery RA, Alachkar N.

BMC Nephrol. 2016 Jan 11;17:7. doi: 10.1186/s12882-015-0219-x.

11.

Glomerulonephritis with isolated C3 deposits and monoclonal gammopathy: a fortuitous association?

Bridoux F, Desport E, Frémeaux-Bacchi V, Chong CF, Gombert JM, Lacombe C, Quellard N, Touchard G.

Clin J Am Soc Nephrol. 2011 Sep;6(9):2165-74. doi: 10.2215/CJN.06180710. Epub 2011 Jul 22.

12.

De novo C3 glomerulonephritis in a renal allograft.

Nahm JH, Song SH, Kim YS, Cheong HI, Lim BJ, Kim BS, Jeong HJ.

Ultrastruct Pathol. 2016;40(2):112-5. doi: 10.3109/01913123.2016.1154634. Epub 2016 Mar 17.

PMID:
26986539
13.

Renal transplantation in patients with dense deposit disease: morphological characteristics of recurrent disease and clinical outcome.

Andresdottir MB, Assmann KJ, Hoitsma AJ, Koene RA, Wetzels JF.

Nephrol Dial Transplant. 1999 Jul;14(7):1723-31.

PMID:
10435883
14.

C3 glomerulonephritis and autoimmune disease: more than a fortuitous association?

Alexander MP, Fervenza FC, De Vriese AS, Smith RJ, Nasr SH, Cornell LD, Herrera Hernandez LP, Zhang Y, Sethi S.

J Nephrol. 2016 Apr;29(2):203-209. doi: 10.1007/s40620-015-0218-9. Epub 2015 Jul 18.

PMID:
26187133
15.

A case of C3 glomerulonephritis successfully treated with eculizumab.

Payette A, Patey N, Dragon-Durey MA, Frémeaux-Bacchi V, Le Deist F, Lapeyraque AL.

Pediatr Nephrol. 2015 Jun;30(6):1033-7. doi: 10.1007/s00467-015-3061-2. Epub 2015 Mar 22.

PMID:
25796589
16.

Proliferative glomerulonephritis secondary to dysfunction of the alternative pathway of complement.

Sethi S, Fervenza FC, Zhang Y, Nasr SH, Leung N, Vrana J, Cramer C, Nester CM, Smith RJ.

Clin J Am Soc Nephrol. 2011 May;6(5):1009-17. doi: 10.2215/CJN.07110810. Epub 2011 Mar 17.

17.

Severe active C3 glomerulonephritis triggered by immune complexes and inactivated after eculizumab therapy.

Kersnik Levart T, Ferluga D, Vizjak A, Mraz J, Kojc N.

Diagn Pathol. 2016 Oct 7;11(1):94.

18.

Recurrent membranoproliferative glomerulonephritis after kidney transplantation.

Lorenz EC, Sethi S, Leung N, Dispenzieri A, Fervenza FC, Cosio FG.

Kidney Int. 2010 Apr;77(8):721-8. doi: 10.1038/ki.2010.1. Epub 2010 Feb 3.

19.

Recurrent membranoproliferative glomerulonephritis type I after kidney transplantation: a 17-year single-center experience.

Green H, Rahamimov R, Rozen-Zvi B, Pertzov B, Tobar A, Lichtenberg S, Gafter U, Mor E.

Transplantation. 2015 Jun;99(6):1172-7. doi: 10.1097/TP.0000000000000459.

PMID:
25340602
20.

Likely Recurrence of C3 Glomerulonephritis in Kidney Transplantation: An Entity to Bear in Mind: Case Report.

Perea-Ortega L, León-Fradejas M, Alonso-Titos J, Cabello-Díaz M, Toledo-Rojas R, Sola-Moyano E, Martín-Reyes G, López-Jiménez V, Burgos-Rodríguez D, Hernández-Marrero D.

Transplant Proc. 2015 Nov;47(9):2669-71. doi: 10.1016/j.transproceed.2015.09.053.

PMID:
26680069

Supplemental Content

Support Center